Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Application of epothilones in breast cancer therapy.

Cianfrocca M.

Curr Opin Oncol. 2008 Nov;20(6):634-8. doi: 10.1097/CCO.0b013e32831270b0. Review.

PMID:
18841044
2.

Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials.

Fornier M.

Clin Breast Cancer. 2010 Oct 1;10(5):352-8. doi: 10.3816/CBC.2010.n.046. Review.

PMID:
20920979
3.

Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.

Yardley DA.

Clin Breast Cancer. 2008 Dec;8(6):487-92. doi: 10.3816/CBC.2008.n.058. Review.

PMID:
19073502
4.

Clinical studies with epothilones for the treatment of metastatic breast cancer.

Vahdat LT.

Semin Oncol. 2008 Apr;35(2 Suppl 2):S22-30; quiz S40. doi: 10.1053/j.seminoncol.2008.02.003. Review.

PMID:
18410796
5.

Clinical experience with epothilones in patients with breast cancer.

Buzdar AU.

Clin Breast Cancer. 2008 Mar;8 Suppl 2:S71-8. Review.

PMID:
18637402
6.

Novel cytotoxic agents: epothilones.

Goodin S.

Am J Health Syst Pharm. 2008 May 15;65(10 Suppl 3):S10-5. doi: 10.2146/ajhp080089. Review.

PMID:
18463327
7.

Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer.

Goodin S.

Am J Health Syst Pharm. 2008 Nov 1;65(21):2017-26. doi: 10.2146/ajhp070628. Review.

PMID:
18945860
8.
9.

Budget impact analysis of ixabepilone used according to FDA approved labeling in treatment-resistant metastatic breast cancer.

Ho J, Zhang L, Todorova L, Whillans F, Corey-Lisle P, Yuan Y.

J Manag Care Pharm. 2009 Jul-Aug;15(6):467-75.

10.

Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.

Vahdat L.

Oncologist. 2008 Mar;13(3):214-21. doi: 10.1634/theoncologist.2007-0167. Review.

11.

Ixabepilone, a new treatment option for metastatic breast cancer.

Toppmeyer DL, Goodin S.

Am J Clin Oncol. 2010 Oct;33(5):516-21. doi: 10.1097/COC.0b013e3181b9cd52. Review.

PMID:
20023567
12.

Preclinical discovery of ixabepilone, a highly active antineoplastic agent.

Lee FY, Borzilleri R, Fairchild CR, Kamath A, Smykla R, Kramer R, Vite G.

Cancer Chemother Pharmacol. 2008 Dec;63(1):157-66. doi: 10.1007/s00280-008-0724-8. Epub 2008 Mar 18. Review.

PMID:
18347795
13.

Ixabepilone for the treatment of breast cancer.

Alvarez RH, Valero V, Hortobagyi GN.

Ann Med. 2011;43(6):477-86. doi: 10.3109/07853890.2011.579151. Epub 2011 May 17. Review.

PMID:
21585248
14.

Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.

Rivera E, Lee J, Davies A.

Oncologist. 2008 Dec;13(12):1207-23. doi: 10.1634/theoncologist.2008-0143. Epub 2008 Dec 16. Review.

15.

Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.

Hortobagyi GN, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Lerzo GL, Pivot XB, Hurtado de Mendoza F, Xu B, Vahdat LT, Peck RA, Mukhopadhyay P, Roché HH.

Breast Cancer Res Treat. 2010 Jul;122(2):409-18. doi: 10.1007/s10549-010-0901-4. Epub 2010 May 8.

PMID:
20454927
16.

The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.

Boehnke Michaud L.

J Oncol Pharm Pract. 2009 Jun;15(2):95-106. doi: 10.1177/1078155208100095. Epub 2009 Jan 26. Review.

PMID:
19171553
17.

Advances in breast cancer treatment: the emerging role of ixabepilone.

Frye DK.

Expert Rev Anticancer Ther. 2010 Jan;10(1):23-32. doi: 10.1586/era.09.158. Review.

PMID:
20014882
18.

Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials.

Valero V, Vrdoljak E, Xu B, Thomas E, Gómez H, Manikhas A, Medina C, Li RK, Ro J, Bosserman L, Vahdat L, Mukhopadhyay P, Opatt D, Sparano JA.

Clin Breast Cancer. 2012 Aug;12(4):240-6. doi: 10.1016/j.clbc.2012.03.013. Epub 2012 Jun 2.

PMID:
22658378
19.

Ixabepilone and other epothilones: microtubule-targeting agents for metastatic breast cancer.

Morris PG, Fornier MN.

Clin Adv Hematol Oncol. 2009 Feb;7(2):115-22.

PMID:
19367253
20.

Ixabepilone.

Stein A.

Clin J Oncol Nurs. 2010 Feb;14(1):65-71. doi: 10.1188/10.CJON.65-71. Review.

PMID:
20118028

Supplemental Content

Support Center